HIV/AIDS Topics HIV11: Complera Combo Pill as Effective as Atripla for First HIV Treatment, but Better Tolerability
- Details
- Category: HIV Treatment
- Published on Tuesday, 20 November 2012 00:00
- Written by Liz Highleyman
The Complera (rilpivirine/tenofovir/emtricitabine) single-tablet regimen suppressed HIV as well as the Atripla (efavirenz/tenofovir/emtricitabine) combination pill in treatment-naive people, but led to fewer adverse events -- in particular neuropsychiatric side effects associated with efavirenz, according to a report at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) last week in Glasgow. 
Coverage of 11th International Congress on Drug Therapy in HIV Infection
- Details
- Category: HIV Treatment
- Published on Saturday, 17 November 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 11th International Congress on Drug Therapy in HIV Infection (HIV11), November 11-15, 2012, Glasgow, Scotland.
Conference highlights include experimental antiretroviral drugs, ART strategies, manging side effects, HIV-related non-AIDS conditions, treatment as prevention and PrEP, HIV/HCV coinfection, and the search for a cure for HIV.
HIVandHepatitis.com HIV11 conference section
ICAAC 2012: Cobicistat-boosted Elvitegravir Does Not Interact with Methadone
- Details
- Category: HIV Treatment
- Published on Tuesday, 13 November 2012 00:00
- Written by Liz Highleyman
The new HIV integrase inhibitor elvitegravir, boosted with cobicistat, does not cause clinically important changes in levels of methadone or buprenorphine used to manage opiate addiction, researchers reported at the recent 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco.
HIV11: Infants Who Start Antiretrovirals Early Keep HIV Suppressed Despite Treatment Interruption
- Details
- Category: HIV Treatment
- Published on Friday, 16 November 2012 00:00
- Written by Liz Highleyman
Babies who started taking lopinavir-based antiretroviral therapy (ART) soon after they were diagnosed with HIV experienced good virological response that was sustained through 6 years, even after they stopped treatment, according to long-term data from the CHER study presented at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) this week in Glasgow.
Many People with HIV Skip Antiretroviral Therapy When They Drink Alcohol
- Details
- Category: HIV Treatment
- Published on Friday, 09 November 2012 00:00
- Written by Liz Highleyman
About half of people who both take antiretroviral therapy (ART) and drink alcohol reported that they sometimes skip medication doses while drinking, according to a cohort study described in the October 12, 2012, advance online edition of the Journal of General Internal Medicine.
HIV11: Dolutegravir Remains Effective for Treatment-experienced People with Multidrug-resistant HIV
- Details
- Category: HIV Treatment
- Published on Friday, 16 November 2012 00:00
- Written by Liz Highleyman
The investigational HIV integrase inhibitor dolutegravir, which has shown comparable or superior efficacy to widely used drugs in clinical trials to date, works well for people with highly resistant HIV, including virus with mutations conferring resistance to other drugs in its class, researchers reported at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) this week in Glasgow.
Pegylated Interferon May Maintain HIV Suppression and Reduce Viral DNA Integration
- Details
- Category: Search for a Cure
- Published on Friday, 09 November 2012 00:00
- Written by Liz Highleyman
Adding pegylated interferon alfa to antiretroviral therapy (ART) for HIV may help some people control viral replication when they interrupt treatment, according to a small study reported at this year's Conference on Retroviruses and Opportunistic Infections (CROI 2012) and published in the October 26, 2012, advance online edition of the Journal of Infectious Diseases.
More Articles...
- Antiretroviral Treatment Lowers Risk of Non-AIDS Illness in People Newly Diagnosed with HIV
- ICAAC 2012: New Tenofovir Pro-drug Matches Potency of Original Version but with Less Toxicity
- HHS Updates Antiretroviral Treatment Guidelines for Children with HIV
- Raltegravir (Isentress) Can Cause Central Nervous System Side Effects for People with HIV
- Resources for People with HIV and Hepatitis and Providers in Disaster Areas
Web Design and Development by